Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wou… Read more
Rafarma Pharmaceuticals Inc (RAFA) - Total Assets
Latest total assets as of March 2025: $12.03 Million USD
Based on the latest financial reports, Rafarma Pharmaceuticals Inc (RAFA) holds total assets worth $12.03 Million USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rafarma Pharmaceuticals Inc - Total Assets Trend (2010–2024)
This chart illustrates how Rafarma Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rafarma Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Rafarma Pharmaceuticals Inc's total assets of $12.03 Million consist of 15.4% current assets and 84.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.6% |
| Accounts Receivable | $1.62 Million | 13.5% |
| Inventory | $156.00K | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Rafarma Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rafarma Pharmaceuticals Inc's current assets represent 15.4% of total assets in 2024, a decrease from 15.5% in 2010.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2024, down from 3.9% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 84.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 13.5% of total assets.
Rafarma Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Rafarma Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Rafarma Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Rafarma Pharmaceuticals Inc generates 0.75x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Rafarma Pharmaceuticals Inc generates $ 2.21 in net profit.
Rafarma Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.13 | 1.23 | 2.98 |
| Quick Ratio | 1.03 | 1.18 | 1.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $207.00K | $ 385.00K | $ 31.07 Million |
Rafarma Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Rafarma Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | $12.03 Million |
| Market Capitalization | $1.35K USD |
Valuation Analysis
Below Book Valuation: The market values Rafarma Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Rafarma Pharmaceuticals Inc's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Rafarma Pharmaceuticals Inc (2010–2024)
The table below shows the annual total assets of Rafarma Pharmaceuticals Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.03 Million | -1.11% |
| 2023-12-31 | $12.16 Million | +0.31% |
| 2023-11-30 | $12.12 Million | -87.67% |
| 2022-12-31 | $98.32 Million | 0.00% |
| 2022-11-30 | $98.32 Million | +10.05% |
| 2021-12-31 | $89.34 Million | 0.00% |
| 2021-11-30 | $89.34 Million | +26.49% |
| 2020-12-31 | $70.63 Million | 0.00% |
| 2020-11-30 | $70.63 Million | +244.11% |
| 2019-12-31 | $20.53 Million | 0.00% |
| 2019-11-30 | $20.53 Million | +223.56% |
| 2018-12-31 | $6.34 Million | 0.00% |
| 2018-11-30 | $6.34 Million | +0.61% |
| 2017-12-31 | $6.31 Million | 0.00% |
| 2017-11-30 | $6.31 Million | -98.63% |
| 2014-12-31 | $460.33 Million | 0.00% |
| 2014-11-30 | $460.33 Million | -0.31% |
| 2013-12-31 | $461.76 Million | 0.00% |
| 2013-11-30 | $461.76 Million | +39.93% |
| 2011-11-30 | $329.99 Million | +13849.57% |
| 2010-11-30 | $2.37 Million | -- |